New combo therapy trial offers hope for tough pancreatic cancer
NCT ID NCT05558982
Summary
This study is testing whether combining two drugs, BXCL701 and pembrolizumab, can help control metastatic pancreatic cancer that has worsened after initial treatment. It will measure if patients' cancer stays stable or shrinks for at least 18 weeks. The trial is for adults with advanced pancreatic cancer who meet specific health criteria and are willing to undergo tumor biopsies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Georgetown Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, 20007, United States
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Medstar Washington Hospital Center
Washington D.C., District of Columbia, 20010, United States
Conditions
Explore the condition pages connected to this study.